Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions...
A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology
BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients suffering from atrial fibrillation (AF) in a groundbreaking study using a next-generation catheter designed to improve the...